ENVALITH
神戸天然物化学株式会社 logo

KNC Laboratories Co., Ltd.

6568・Growth Market・Services

Official website
神戸天然物化学株式会社 logo
KNC Laboratories Co., Ltd.6568

Business

Kobe Natural Products Chemical was founded in 1985 as a specialized contract organic chemicals company. For product development companies such as pharmaceutical and chemical firms, it provides an integrated suite of compound synthesis solutions, ranging from small-quantity sample synthesis at the research stage, to mass-production studies at the development stage, and mass production for commercial sale. The business is organized into three divisions: Functional Materials Business Division (display materials, semiconductor manufacturing chemicals, agrochemicals, etc.), Pharmaceutical Business Division (active pharmaceutical ingredients, clinical trial APIs, intermediates), and Bio Business Division (chemical substance synthesis using genetically modified microorganisms, auxiliary agents for antibody drug manufacturing, etc.). The company has research and manufacturing sites in Kobe, Izumo, and Ichikawa, with major clients including large corporations such as Torii Pharmaceutical, Daiichi Sankyo, and Toray. Net sales for FY2026 (ending March 2026) were ¥9,094 million.

Business Model

The company employs a "stage-up growth" model in which order volumes and unit prices from the company expand in stages as customers' product development progresses from research to development to mass production. The mass-production stage consistently accounts for over 60% of sales, securing continuous large-scale orders. Through the division-of-labor structure of contract synthesis, customers can focus on functional evaluation research, while the company adds value by providing synthesis research reports. The company's revenue structure is designed to accelerate the capture of mass-production projects by continuously investing in facilities and human resource development to expand production capacity.

Company Strengths

The company operates research, development, and mass-production facilities across multiple sites, including the Izumo No. 1 and No. 2 Plants, the KNC Bio Research Center, and the Kobe Research Institute, enabling it to provide solutions at every stage. In FY2026 (ending March 2026), the company completed Building D of the KNC Bio Research Center (investment of ¥2,690 million) and Building FP4 of the Izumo No. 2 Plant (¥2,666 million), substantially expanding production capacity.

Through the practice of the Stage-Up Growth Model, the proportion of sales from mass-production stage products has stably remained above 60%. In FY2026 (ending March 2026), the order backlog stood at a high level of ¥6,403 million (121.0% year on year), with the Pharmaceutical Business Division's backlog of ¥4,259 million and the Bio Business Division's backlog of ¥593 million establishing a structure that underpins sales in subsequent periods.

The three-division structure comprising Functional Materials (sales of ¥3,057 million), Pharmaceutical (¥3,928 million), and Bio (¥2,109 million) diversifies dependence on any specific field. In FY2026 (ending March 2026), the Bio Business Division showed high growth of 26.5% year on year and the Pharmaceutical Business Division 11.9% year on year, while the Functional Materials Business Division carried out advance production for large-scale projects destined for the following period, which also embeds a carry-over effect on sales into the next period.

ENVALITH's Perspective

FY2026 (ending March 2026) recorded net sales of ¥9,093 million (up 11.2% year on year) and operating income of ¥1,024 million (up 32.7% year on year), demonstrating a clear recovery. However, compared with operating income of ¥2,081 million in FY2024 (ended March 2024), the level remains at roughly half. Depreciation expense increased sharply from ¥830 million in the previous fiscal year to ¥1,233 million, and the structure in which higher fixed costs associated with the new building's operation are capping the ceiling of profit recovery continues. Whether the revenue increase effect can outweigh the rise in fixed costs will be the focus going forward.

The company has explicitly stated that the de facto closure of the Strait of Hormuz from March 2026 onward is causing serious disruption to the supply of petrochemical products, a key raw material. It has deemed it "reasonably difficult to calculate" full-year earnings guidance for FY2027 (ending March 2027) and left it undetermined, disclosing only its first-quarter outlook (net sales of ¥2,000 million, operating income of ¥95 million). As an external factor, assessing the impact of rising crude oil and LNG prices and supply chain disruption on manufacturing costs and production plans has become the most critical variable for investment decisions.

Capital expenditures on tangible fixed assets in FY2026 (ending March 2026) declined to ¥2,626 million from ¥3,300 million in the previous fiscal year, and with construction in progress falling to zero, the completion of one investment cycle can be confirmed. Meanwhile, total deferred revenue (current and non-current) increased significantly to approximately ¥2,408 million (from approximately ¥1,771 million in the previous fiscal year), reflecting a buildup of advance payments received from customers. The balance between the timing of revenue recognition for this deferred revenue and the pressure on profit from rising personnel training and recruitment costs as well as increased depreciation from the new building will hold the key to FY2027 (ending March 2027) performance.

Growth Strategy

Building a sustainable growth foundation through expanded mass production from new plant operations and the acquisition of medium-molecule and bio technologies

Building D began operations from the fourth quarter of FY2026 (ending March 2026), and Bio Business Division sales reached ¥2,109 million (original source figure in thousands of yen), up 26.5% year on year. The effects of the new building are beginning to materialize, with both the mass production stage and development stage progressing favorably. Future improvement in the utilization rate will be the key driver of earnings improvement going forward.

The company continues to invest in R&D aimed at acquiring new technologies in the medium-molecule pharmaceutical and biopharmaceutical fields. R&D is also being conducted in parallel to secure new API manufacturing projects. This is positioned as an advance investment aimed at expanding the future mass production pipeline, and the favorable progress of development-stage projects reflects part of the results of this effort.

The company continues its policy of aggressive investment in personnel development and recruitment as a foundation for future growth. For FY2027 (ending March 2027), increases in personnel development and recruitment costs, as well as higher personnel expenses due to headcount growth, are expected. While this will be a factor pressuring profits in the short term, the company maintains its stance of prioritizing the strengthening of production capacity and technical capabilities over the medium to long term.

The policy is to absorb the increase in depreciation expenses associated with the new building's operation (¥1,233 million in FY2026 (ending March 2026), versus ¥879 million in the previous fiscal year) through the effect of higher sales and manufacturing rationalization. In FY2026 (ending March 2026), the effect of higher sales exceeded the increase in fixed costs, resulting in higher profits. However, the company explains that in FY2027 (ending March 2027), profit pressure is expected due to a further increase in depreciation expenses associated with the operation of the new plant building.

Last updated: July 19, 2026